experimental neoplasms

Summary

Summary: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.

Top Publications

  1. ncbi Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    D Lyden
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Nat Med 7:1194-201. 2001
  2. ncbi Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
    M S O'Reilly
    Department of Surgery, Children s Hospital, Boston, Massachusetts 02115, USA
    Cell 88:277-85. 1997
  3. ncbi Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
    T Kamijo
    Howard Hughes Medical Institute, Department of Tumor Cell Biology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cell 91:649-59. 1997
  4. pmc Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts
    M A Konerding
    Department of Anatomy, Johannes Gutenberg University Mainz, Germany
    Br J Cancer 80:724-32. 1999
  5. ncbi The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects
    Ann M Bode
    The Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, USA
    Crit Rev Oncol Hematol 42:5-24. 2002
  6. ncbi Genetic background controls tumor development in PTEN-deficient mice
    Dan Freeman
    Department of Molecular and Medical Pharmacology, University of California at Los Angeles School of Medicine, 650 C E Young Drive South, Los Angeles, CA 90095, USA
    Cancer Res 66:6492-6. 2006
  7. ncbi CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ
    S Radoja
    Department of Cell Biology and Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 166:6074-83. 2001
  8. ncbi Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
    L A Donehower
    Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030
    Nature 356:215-21. 1992
  9. ncbi Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
    M A Blasco
    Cold Spring Harbor Laboratory, New York 11724, USA
    Cell 91:25-34. 1997
  10. ncbi Histone deacetylases and cancer: causes and therapies
    P Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 1:194-202. 2001

Research Grants

Detail Information

Publications258 found, 100 shown here

  1. ncbi Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    D Lyden
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Nat Med 7:1194-201. 2001
    ..These data demonstrate that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggest new clinical strategies to block tumor growth...
  2. ncbi Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
    M S O'Reilly
    Department of Surgery, Children s Hospital, Boston, Massachusetts 02115, USA
    Cell 88:277-85. 1997
    ..Together with angiostatin data, these findings validate a strategy for identifying endogenous angiogenesis inhibitors, suggest a theme of fragments of proteins as angiogenesis inhibitors, and demonstrate dormancy therapy...
  3. ncbi Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
    T Kamijo
    Howard Hughes Medical Institute, Department of Tumor Cell Biology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cell 91:649-59. 1997
    ..Therefore, INK4a encodes growth inhibitory proteins that act upstream of the retinoblastoma protein and p53. Mutations and deletions targeting this locus in cancer cells are unlikely to be functionally equivalent...
  4. pmc Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts
    M A Konerding
    Department of Anatomy, Johannes Gutenberg University Mainz, Germany
    Br J Cancer 80:724-32. 1999
    ..In all tumours, the variability of the vessel diameters was significantly higher than in normal tissue. The quantitative data provide strong evidence for a characteristic vascular network determined by the tumour cells themselves...
  5. ncbi The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects
    Ann M Bode
    The Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, USA
    Crit Rev Oncol Hematol 42:5-24. 2002
    ..The primary purpose of this review is to examine recent findings, from this laboratory and others, that focus on the molecular mechanisms of arsenic's actions in cell transformation and as a therapeutic agent...
  6. ncbi Genetic background controls tumor development in PTEN-deficient mice
    Dan Freeman
    Department of Molecular and Medical Pharmacology, University of California at Los Angeles School of Medicine, 650 C E Young Drive South, Los Angeles, CA 90095, USA
    Cancer Res 66:6492-6. 2006
    ..Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation...
  7. ncbi CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ
    S Radoja
    Department of Cell Biology and Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 166:6074-83. 2001
    ..Our data demonstrate that TIL, not tumor, express both Fas and FasL, are arrested in G(1), do not secrete cytokine in situ, and, upon activation in vitro and in vivo, rapidly die by activation-induced cell death...
  8. ncbi Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
    L A Donehower
    Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030
    Nature 356:215-21. 1992
    ....
  9. ncbi Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
    M A Blasco
    Cold Spring Harbor Laboratory, New York 11724, USA
    Cell 91:25-34. 1997
    ..These results indicate that telomerase is essential for telomere length maintenance but is not required for establishment of cell lines, oncogenic transformation, or tumor formation in mice...
  10. ncbi Histone deacetylases and cancer: causes and therapies
    P Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 1:194-202. 2001
    ..HDAC inhibitors are proving to be an exciting therapeutic approach to cancer, but how do they exert this effect?..
  11. ncbi Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
    Ruth Ganss
    Department of Molecular Immunology, German Cancer Research Center, 69120 Heidelberg, Germany
    Cancer Res 62:1462-70. 2002
    ..Therefore, irradiation/adoptive transfer therapy combines antigen-driven tumor cell eradication with anti-angiogenic effects on tumor endothelium, a powerful synergy that has not been previously appreciated...
  12. pmc Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer
    Ming Zhao
    AntiCancer Inc, 7917 Ostrow Street, San Diego, CA 92111, USA
    Proc Natl Acad Sci U S A 104:10170-4. 2007
    ..The approach described here, where bacterial monotherapy effectively treats metastatic prostate tumors, is a significant improvement over previous bacterial tumor-therapy strategies that require combination with toxic chemotherapy...
  13. ncbi Tumor spectrum analysis in p53-mutant mice
    T Jacks
    Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139
    Curr Biol 4:1-7. 1994
    ..The construction of mouse strains carrying germline mutations of p53 facilitates analysis of the function of p53 in normal cells and tumorigenesis...
  14. pmc Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence
    Akitake Mukasa
    Ludwig Institute for Cancer Research, University of California, San Diego, CA 92039, USA
    Proc Natl Acad Sci U S A 107:2616-21. 2010
    ..Such alternative pathways function as substitutes for DeltaEGFR signaling and should therefore be considered as potential targets for additional therapy...
  15. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  16. ncbi Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
    D Lyden
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 401:670-7. 1999
    ..Because the Id genes are expressed at very low levels in adults, they make attractive new targets for anti-angiogenic drug design...
  17. pmc Differential tumor surveillance by natural killer (NK) and NKT cells
    M J Smyth
    Cellular Cytotoxicity Laboratory, Austin Research Institute, Austin and Repatriation Medical Centre, Heidelberg, 3084 Victoria, Australia
    J Exp Med 191:661-8. 2000
    ..This is the first description of an antitumor function for NKT cells in the absence of exogenously administered potent stimulators such as IL-12 or alpha-galactosylceramide...
  18. ncbi A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion
    Georgios T Stathopoulos
    Applied Biomedical Research and Training Center Marianthi Simou, Department of Critical Care and Pulmonary Services, General Hospital Evangelismos, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
    J Natl Cancer Inst 100:1464-76. 2008
    ..Tumor cells in malignant pleural effusions (MPEs) are an important source of monocyte chemoattractant protein (MCP)-1. However, the role of tumor-derived MCP-1 in the pathogenesis and progression of MPE has not been determined...
  19. ncbi Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine
    Andrew R Haas
    Thoracic Oncology Research Laboratory, Philadelphia, Pennsylvania 19104 6160, USA
    Clin Cancer Res 12:214-22. 2006
    ..This study shows that the effectiveness of a cancer vaccine can be significantly improved by adding COX-2 inhibition...
  20. ncbi Cooperative tumorigenic effects of germline mutations in Rb and p53
    B O Williams
    Department of Biology, Massachusetts Institute of Technology, Cambridge 02139
    Nat Genet 7:480-4. 1994
    ..These data indicate that mutations in Rb and p53 can cooperate in the transformation of certain cell types in the mouse...
  21. ncbi VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
    David F Stojdl
    Ottawa Regional Cancer Centre Research Laboratories, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Cancer Cell 4:263-75. 2003
    ..While highly attenuated for growth in normal mice, both AV1 and AV2 effected complete and durable cures in the majority of treated animals when delivered systemically...
  22. ncbi Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
    C Deng
    Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 82:675-84. 1995
    ..These results establish the role of p21CIP1/WAF1 in the G1 checkpoint, but suggest that the anti-apoptotic and the anti-oncogenic effects of p53 are more complex...
  23. ncbi Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?
    J Denekamp
    Department of Oncology, Umea University, Sweden Juliana
    Adv Enzyme Regul 38:281-99. 1998
    ....
  24. pmc Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    Yoshiko Iwai
    Department of Medical Chemistry, Graduate School of Medicine, Japan Science and Technology Corporation, Kyoto 606 8501, Japan
    Proc Natl Acad Sci U S A 99:12293-7. 2002
    ....
  25. pmc Module map of stem cell genes guides creation of epithelial cancer stem cells
    David J Wong
    Program in Epithelial Biology, Stanford University, Stanford, CA 94305, USA
    Cell Stem Cell 2:333-44. 2008
    ..Thus, activation of an ESC-like transcriptional program in differentiated adult cells may induce pathologic self-renewal characteristic of cancer stem cells...
  26. ncbi The urokinase-type plasminogen activator system in cancer metastasis: a review
    P A Andreasen
    Department of Molecular and Structural Biology, University of Aarhus, Denmark
    Int J Cancer 72:1-22. 1997
    ..A detailed knowledge of these processes is necessary for utilization of the therapeutic potential of interfering with the action of the system in cancers...
  27. pmc Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2)
    Mohammad T Malik
    Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY, USA
    Mol Cancer 5:61. 2006
    ..In the present study, we investigated the effect of overexpression of PTTG on secretion and expression of metastasis-related metalloproteinase-2 (MMP-2) in HEK293 cells, cell migration, invasion and tubule formation...
  28. ncbi Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic
    R M Hoffman
    AntiCancer, Inc, San Diego, CA 92111, USA
    Invest New Drugs 17:343-59. 1999
    ..These unique SOI models have been used for innovative drug discovery and mechanism studies and serve as a bridge linking pre-clinical and clinical research and drug development...
  29. pmc An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum
    M J Smyth
    Cellular Cytotoxicity Laboratory, The Austin Research Institute, Heidelberg, Victoria 3084, Australia
    J Exp Med 188:1611-9. 1998
    ..Overall, these data show that NK cells delivering perforin are the major effectors of class I- tumor rejection in the peritoneum, and that TNF is specifically critical for their recruitment to the peritoneum...
  30. pmc Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
    Aarif Y Khakoo
    Laboratory of Molecular Biology, Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1235-47. 2006
    ....
  31. ncbi The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability
    D A Beauregard
    Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, United Kingdom
    Cancer Res 61:6811-5. 2001
    ....
  32. ncbi Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate
    D J Chaplin
    Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, U K
    Anticancer Res 19:189-95. 1999
    ..In summary, the studies confirm combretastatin A4 phosphate as a novel agent which targets and damages tumour vasculature and, moreover, indicate its potential therapeutic usefulness as an adjuvant to conventional cytotoxic approaches...
  33. ncbi p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent
    C J Kemp
    Fred Hutchinson Cancer Research Center, Seattle, Washington 90109 1024, USA
    Cancer Res 61:327-32. 2001
    ..This variation provides one explanation for the tissue specificity of tumor suppression by p53. It also indicates that the role of apoptosis in the response of tumors to therapy varies significantly among tumor types...
  34. ncbi Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model
    B Chen
    Laboratorium voor Farmaceutische Biologie en Fytofarmacologie, Faculteit Farmaceutische Wetenschappen, K.U. Leuven, Van Evenstraat 4, B-3000 Leuven, Belgium
    Int J Cancer 93:275-82. 2001
    ..Hypericin distribution and PDT response studies revealed a close correlation between the plasma drug level and the PDT effects, which suggests that vascular damage is the primary effect of hypericin-mediated PDT in this tumor model...
  35. ncbi Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity
    S K Sahoo
    Department of Microbiology, Kumamoto University School of Medicine, 2 2 1 Honjo, Kumamoto 860 0811, Japan
    Bioconjug Chem 13:1031-8. 2002
    ..12 microM. Most important, PEG-ZnPP injected intravenously significantly suppressed intratumor HO activity in a murine solid tumor model, which suggests that tumor-targeted inhibition of HO is possible with the use of PEG-ZnPP...
  36. ncbi CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells
    Z Qin
    Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Immunity 12:677-86. 2000
    ..This shows that an effective anti-tumor response involves communication between CD4+ T cells and nonhematopoietic cells, most likely within the tumor stroma, and that tumor immunity must not entirely rely on direct tumor cell killing...
  37. pmc Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
    Bin Zhang
    Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA
    J Exp Med 204:49-55. 2007
    ..Under these conditions, tumor rejection was complete. These findings may set the stage for developing rational clinical protocols for combining irradiation or chemotherapy with CTL therapy...
  38. pmc B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism
    Xingluo Liu
    Department of Pathology, Ohio State University Medical Center, Columbus, OH 43210, USA
    J Exp Med 197:1721-30. 2003
    ..Our results demonstrate a novel pathway for B7DC to promote tumor immunity and may reconcile the apparently contradictory findings on the function of B7DC...
  39. ncbi Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila
    Tatsushi Igaki
    Howard Hughes Medical Institute, Department of Genetics, Yale University School of Medicine, Boyer Center for Molecular Medicine, 295 Congress Avenue, New Haven, Connecticut 06536, USA
    Curr Biol 16:1139-46. 2006
    ..Similar oncogenic cooperation mediated through these evolutionarily conserved signaling pathways could contribute to human cancer progression...
  40. ncbi Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis
    S E Street
    Cancer Immunology, Peter MacCallum Cancer Institute, Victoria, Australia
    Blood 97:192-7. 2001
    ....
  41. ncbi Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer
    F Burke
    Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK
    Cytokines Cell Mol Ther 5:51-61. 1999
    ....
  42. ncbi Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700
    K Hori
    Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai
    Jpn J Cancer Res 90:1026-38. 1999
    ..AC7700 has been demonstrated to be a promising anticancer compound which has such an action...
  43. ncbi Cachexia in experimental models
    P W Emery
    Department of Nutrition and Dietetics, King s College London, UK
    Nutrition 15:600-3. 1999
    ....
  44. ncbi Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition
    Syed S A Qadri
    Cork University Hospital, Wilton, Cork, Republic of Ireland
    Ann Thorac Surg 79:990-5; discussion 990-5. 2005
    ..Even after apparently curative resection, lung cancer recurrence continues to lead to high mortality levels. The aim of this study was to assess the effects of cyclooxygenase-2 (COX-2) inhibitor on local and systemic recurrent tumor growth...
  45. ncbi The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice
    I M Svane
    Department of Oncology, Herlev Hospital University of Copenhagen, Denmark
    Med Oncol 16:223-38. 1999
    ..In this review, we discuss the difficulties facing immunotherapy when conclusions are drawn from the presented observations and hypotheses...
  46. ncbi Tumor spectrum in ARF-deficient mice
    T Kamijo
    Howard Hughes Medical Institute, and Department of Tumor Cell Biology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 59:2217-22. 1999
    ..The longer latency of tumor formation in ARF-null versus p53-null mice, therefore, appears to enable a broader spectrum of tumors to emerge...
  47. pmc p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene
    Sophie Vasseur
    Centre de Recherche INSERM, EMI 0116, 163 Avenue de Luminy, Campus de Luminy, BP 172, F 13009 Marseille, France
    EMBO Rep 3:165-70. 2002
    ..It was concluded that p8 expression in transformed MEFs is necessary for tumour formation, suggesting that the stress-response mechanisms governed by p8 are required for tumour establishment...
  48. ncbi In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: effect of carbogen-breathing
    Govindasamy Ilangovan
    EPR Center, Division of Cardiology, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    Magn Reson Med 48:723-30. 2002
    ....
  49. ncbi Minor histocompatibility antigen-specific MHC-restricted CD8 T cell responses elicited by heat shock proteins
    Jacques Robert
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Immunol 168:1697-703. 2002
    ..e., gp96 purified from normal tissue also generates a significant antitumor response); this suggests a prominent contribution of an innate type of response in the absence of MHC class I Ags...
  50. ncbi Exercise and the immune system: regulation, integration, and adaptation
    B K Pedersen
    Department of Infectious Diseases and Copenhagen Muscle Research Centre, University of Copenhagen, Copenhagen, Denmark
    Physiol Rev 80:1055-81. 2000
    ..Accordingly, drawing on the experimental, clinical, and epidemiological literature, we address the interactions between exercise and infectious diseases as well as exercise and neoplasia within the context of both aging and nutrition...
  51. pmc Tumours can act as adjuvants for humoral immunity
    D M Brown
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA
    Immunology 102:486-97. 2001
    ..Furthermore, co-injection of both B16/OVA and line 1 tumours resulted in production of anti-OVA antibody, indicating that B16 tumours were not immunosuppressive, but instead line 1 tumours appear to exert an adjuvant effect...
  52. ncbi Clostridium spores as anti-tumour agents
    Lieve Van Mellaert
    Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    Trends Microbiol 14:190-6. 2006
    ..These recent developments are reviewed and the reintroduction of this tumour-targeting protein delivery system into clinical settings is discussed...
  53. ncbi Effect of p53 status on tumor response to antiangiogenic therapy
    Joanne L Yu
    Sunnybrook and Women s College Health Sciences Centre, Molecular and Cellular Biology Research, Room S 218, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Science 295:1526-8. 2002
    ....
  54. ncbi Bystander elimination of antigen loss variants in established tumors
    Michael T Spiotto
    Department of Pathology and the Committee on Immunology, The University of Chicago, Chicago, Illinois 60637, USA
    Nat Med 10:294-8. 2004
    ..These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells...
  55. ncbi Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
    W M Kast
    The Netherlands Cancer Institute, Amsterdam
    Cell 59:603-14. 1989
    ..Our data show an important role for CTLs directed against a viral nuclear oncogene product in tumor eradication...
  56. ncbi Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
    J B Sunwoo
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:1419-28. 2001
    ..We conclude that PS-341 inhibits activation of NF-kappa B pathway components related to cell survival, tumor growth, and angiogenesis in SCC...
  57. pmc Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth
    Susanna Purhonen
    Academy of Finland Center of Excellence in Cancer Biology and Molecular Cancer Biology Laboratory, Molecular Cancer Biology Research Program, University of Helsinki, P O Box 63, 00014, Helsinki, Finland
    Proc Natl Acad Sci U S A 105:6620-5. 2008
    ..Endothelial differentiation is not a typical in vivo function of normal BM-derived stem cells in adults, and it has to be an extremely rare event if it occurs at all...
  58. pmc SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
    J M Brown
    Department of Radiation Oncology, Stanford University, California 94305
    Br J Cancer 67:1163-70. 1993
    ..Finally, the major unanswered questions on the drug are outlined...
  59. ncbi The murine gene p27Kip1 is haplo-insufficient for tumour suppression
    M L Fero
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Nature 396:177-80. 1998
    ..Hence, p27 is haplo-insufficient for tumour suppression. The assumption that null mutations in tumour-suppressor genes are recessive excludes those genes that exhibit haplo-insufficiency...
  60. ncbi Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
    K Nakamura
    Department of Molecular Medicine, Sapporo Medical University, Sapporo, Japan
    Gene Ther 11:1155-64. 2004
    ..Thus, gene therapy employing MSCs as a targeting vehicle would be promising as a new therapeutic approach for refractory brain tumor...
  61. ncbi Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR
    R B Luwor
    Ludwig Institute for Cancer Research, Melbourne Branch, Tumour Targeting Program, Austin and Repatriation Medical Centre, Heidelberg 3084, Victoria, Australia
    Cancer Res 61:5355-61. 2001
    ..This study demonstrates that mAb 806 possesses significant antitumor activity...
  62. ncbi Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 7:1459-65. 2001
    ....
  63. pmc scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila
    Anthony M Brumby
    Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, Victoria 8006, Australia
    EMBO J 22:5769-79. 2003
    ....
  64. ncbi A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells
    M Schwab
    Nature 303:497-501. 1983
    ..Amplification and enhanced expression of cellular oncogenes may contribute to the genesis and/or maintenance of at least some naturally occurring tumours...
  65. pmc Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined
    D J Honess
    MRC Unit, MRC Centre, Cambridge, UK
    Br J Cancer 71:1175-80. 1995
    ....
  66. pmc The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
    Yang Yang
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Blood 110:2041-8. 2007
    ....
  67. pmc Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway
    Martina Schwarzkopf
    Brookdale Department of Molecular, Cell, and Developmental Biology, Mount Sinai Medical School, New York, New York 10029, USA
    Genes Dev 20:3440-52. 2006
    ..Taken together, these results show a novel role for p53 in mediating muscle stem cell behavior and muscle atrophy, and point to new targets for the therapeutic treatment of muscle wasting...
  68. ncbi Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts
    David Checkley
    Enabling Science and Technology, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Magn Reson Imaging 21:475-82. 2003
    ..Collectively these studies suggest that DCEMRI using gadopentetate may have potential clinically, for monitoring inhibition of VEGF signaling in solid tumors...
  69. ncbi A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells
    Zhihai Qin
    Institute of Immunology, University Clinic Benjamin Franklin, Free University of Berlin, 12200 Berlin, Germany
    Cancer Res 63:4095-100. 2003
    ..Taken together with our previous findings, we conclude that IFN-gamma-dependent antiangiogenesis is a general mechanism involved in tumor rejection by CD4(+) and CD8(+) T-cell effectors...
  70. ncbi Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun
    Matthew R Young
    Basic Research Laboratory, National Institute of Cancer Frederick, Maryland, USA
    Mol Carcinog 34:72-7. 2002
    ..We showed that expression of TAM67 protected mice from HPV-16 E7-enhanced tumorigenesis, suggesting AP-1 as a target for prevention of HPV-induced cancer...
  71. ncbi Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity
    H Zheng
    Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    J Immunol 167:6731-5. 2001
    ..It also establishes a principle of bridging innate and adaptive immunity for cancer immunotherapy by surface targeting of an intracellular heat shock protein...
  72. ncbi A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
    Y Nihei
    Pharmaceutical Research Laboratories, Ajinomoto Co, Inc, Kawasaki
    Jpn J Cancer Res 90:1016-25. 1999
    ..These results suggest that AC-7700 is a novel antivascular agent that may have potent activity against advanced-stage cancer in the clinical setting...
  73. ncbi A method that allows easy characterization of tumor-infiltrating lymphocytes
    D W Kowalczyk
    The Wistar Institute, 3601 Spruce St, 19104, Philadelphia, PA, USA
    J Immunol Methods 253:163-75. 2001
    ..Progressing tumors that lacked the target antigen for the activated CD8(+) T cell population did not show this selective enrichment...
  74. pmc Tumor rejection by disturbing tumor stroma cell interactions
    S Ibe
    , 13092 Berlin, Germany
    J Exp Med 194:1549-59. 2001
    ..These events preceded hemorrhagic necrosis and residual tumor cell elimination by T cells. Together, T cells regulate the function of TIMs and tumor rejection can be induced by disturbing the stroma network...
  75. pmc Bacteriolytic therapy can generate a potent immune response against experimental tumors
    Nishant Agrawal
    Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 101:15172-7. 2004
    ..Similar effects were observed in rabbits with intrahepatic tumors. It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors...
  76. ncbi Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
    A Chuntharapai
    Department of Antibody Technology, Genentech, South San Francisco, CA 94080, USA
    J Immunol 166:4891-8. 2001
    ..Anti-DR4 mAbs of the IgG1 isotype may provide a useful tool for investigating the therapeutic potential of death receptor targeting in cancer...
  77. pmc Imaging angiogenesis and the microenvironment
    Dai Fukumura
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    APMIS 116:695-715. 2008
    ..Restoring the balance of pro- and anti-angiogenic factors in tumors may "normalize" tumor vasculature and thus improve its function. Administration of cytotoxic therapy during the vascular normalization would enhance its efficacy...
  78. ncbi Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells
    Suyun Huang
    Department of Cancer Biology, Box 173, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, TX 77030, USA
    Oncogene 21:2504-12. 2002
    ..Collectively, these data demonstrate that Stat1 expressed by tumor cells is a negative regulator of tumor angiogenesis and, hence, tumor growth and metastasis...
  79. pmc Foscan uptake and tissue distribution in relation to photodynamic efficacy
    P Cramers
    Experimental Therapy H6, The Netherlands Cancer Institute Antoni van Leeuwenhoeck Ziekenhuis, Amsterdam
    Br J Cancer 88:283-90. 2003
    ..We suggest that the PDT effect, in both tumours and normal tissues, is largely mediated via vascular damage and that the selectivity of PDT is not based on differential tumour drug uptake...
  80. ncbi Lack of carcinogenicity of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in cynomolgus monkeys
    K Ogawa
    Nagoya City University Medical School
    Jpn J Cancer Res 90:622-8. 1999
    ....
  81. ncbi Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication
    Geertje J D van Mierlo
    Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands
    J Immunol 173:6753-9. 2004
    ..Together these results indicate that dendritic cells, depending on their activation state, orchestrate the outcome of CTL-mediated immunity against tumors, leading either to an ineffective immune response or potent antitumor immunity...
  82. ncbi Long-term toxicity and carcinogenicity study of cyclamate in nonhuman primates
    S Takayama
    Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    Toxicol Sci 53:33-9. 2000
    ....
  83. ncbi Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate
    S T Russell
    Nutritional Biomedicine, School of Life and Health Sciences, Aston University, Birmingham, UK
    Cancer Chemother Pharmacol 64:517-27. 2009
    ..To determine the effectiveness of the polyanionic, metal binding agent D-myo-inositol-1,2,6-triphosphate (alpha trinositol, AT), and its hexanoyl ester (HAT), in tissue wasting in cancer cachexia...
  84. ncbi A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models
    Chang Woo Lee
    Biopotency Evaluation Laboratory, Korea Research Institute of Bioscience and Biotechnology, 305 333, Taejon, South Korea
    Biochem Pharmacol 64:473-80. 2002
    ..These results suggest that DW2282, an S-isomer, could be a novel antitumor candidate with higher specificity and lower toxicity than other orally active sulfonylureas...
  85. pmc Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium
    Ming Zhao
    AntiCancer, 7917 Ostrow Street, San Diego, CA 92111 3604, USA
    Proc Natl Acad Sci U S A 102:755-60. 2005
    ..This result is in marked contrast to bacteria previously tried for cancer therapy that were confined to necrotic areas of the tumor, which may account, in part, for the strain's unique antitumor efficacy...
  86. ncbi Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin
    Frits Aarts
    410 Department of Surgery, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    Ann Surg Oncol 14:533-40. 2007
    ..Radioimmunotherapy (RIT) as adjuvant therapy after CS of CRC has been shown to prolong survival in preclinical studies. However, the optimal setting of RIT remains to be determined...
  87. pmc Gamma delta T cells provide an early source of interferon gamma in tumor immunity
    Yunfei Gao
    Section of Rheumatology, Yale School of Medicine, 300 Cedar Street, CAB Building Room S517, New Haven, CT 06520, USA
    J Exp Med 198:433-42. 2003
    ..These results demonstrate that gammadelta T cells can play a necessary role in tumor immunity through provision of an early source of IFN-gamma that in turn may regulate the function of tumor-triggered alphabeta T cells...
  88. ncbi Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy
    Christina Ebbinghaus
    Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland
    Int J Cancer 116:304-13. 2005
    ....
  89. ncbi T cells targeted against a single minor histocompatibility antigen can cure solid tumors
    Marie Christine Meunier
    Institute of Research in Immunology and Cancer, University of Montreal, C P 6128, Downtown Station, Montreal, Quebec, Canada, H3C 3J7
    Nat Med 11:1222-9. 2005
    ..Our preclinical model yields unique insights into how minor H antigen-based immunotherapy could be used to treat human solid tumors...
  90. ncbi The Mouse Tumor Biology Database: integrated access to mouse cancer biology data
    Debra Krupke
    The Jackson Laboratory, Bar Harbor, Maine, USA
    Exp Lung Res 31:259-70. 2005
    ....
  91. ncbi Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies
    Tamer A Elbayoumi
    Department of Pharmaceutical Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington Avenue, Boston, MA 02115, USA
    Eur J Nucl Med Mol Imaging 33:1196-205. 2006
    ....
  92. ncbi Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice
    Zhongjun Zhou
    Department of Biochemistry, Faculty of Medicine, University of Hong Kong, 21 Sassoon Road, Hong Kong, ROC
    Cancer Res 64:4699-702. 2004
    ..In the mouse corneal angiogenesis model, FGF-2-induced neovascularization was significantly impaired in Hspg2(Delta3/Delta3) mutant mice. Our results suggest that HS in perlecan positively regulates the angiogenesis in vivo...
  93. ncbi Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression
    Yuki Hamano
    Center for Matrix Biology, Department of Medicine and the Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 64:1570-4. 2004
    ..This study also makes a strong case for TSP-1 expression levels as a potential predictive marker for the successful use of LDC in cancer patients...
  94. ncbi HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice
    David Finkle
    Department of Physiology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 10:2499-511. 2004
    ....
  95. ncbi Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
    Jane A Plumb
    Department of Medical Oncology, University of Glasgow, Cancer Research United Kingdom Beatson Laboratories, Glasgow, G61 1BD, United Kingdom
    Mol Cancer Ther 2:721-8. 2003
    ..Furthermore, the ability to measure histone acetylation in blood samples could provide a suitable pharmacodynamic end point to monitor drug activity...
  96. pmc Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas
    K Inoue
    Department of Tumor Cell Biology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Genes Dev 15:2934-9. 2001
    ..Although p53 mutations or Arf deletion normally occur in approximately 50% of E(mu)-Myc-induced lymphomas, Dmp1 loss obviates selection for such mutations, indicating that Dmp1 is a potent genetic modifier of the Arf-p53 pathway in vivo...
  97. ncbi Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA
    K Rubin
    Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden
    Int J Cancer 86:636-43. 2000
    ..Our data demonstrate that adjuvant treatment with PGE(1) lowers TP(IF), and enhances transport into the tumors. This principle may be of value as adjuvant therapy in treatment of solid malignancies with currently used anticancer drugs...
  98. ncbi 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner
    Robert E Miller
    Department of Cancer Biology, Immunex Research and Development, Seattle, WA 98101, USA
    J Immunol 169:1792-800. 2002
    ..Finally, in mice in which the number of dendritic cells had been expanded by Fms-like tyrosine kinase3 ligand treatment, the antitumor effects of 4-1BB ligation were enhanced...
  99. ncbi The IkappaB kinase - a bridge between inflammation and cancer
    Michael Karin
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, Cancer Center, School of Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0723, La Jolla, CA 92093 0723, USA
    Cell Res 18:334-42. 2008
    ..Unlike cancer cells, inflammatory cells retain a normal and stable genome and therefore are unlikely to become genetically resistant to therapeutic intervention...
  100. pmc Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells
    G One Ahn
    Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, 269 Campus Drive, CCSR South, Room 1255, Stanford, CA 94305, USA
    Cancer Cell 13:193-205. 2008
    ..Our results suggest that MMP-9 could be an important target for adjunct therapy to enhance the response of tumors to radiotherapy...
  101. ncbi The tumorigenicity diversification in human embryonic kidney 293 cell line cultured in vitro
    Chao Shen
    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China
    Biologicals 36:263-8. 2008
    ..Meanwhile, we also find that high-passage HEK 293 can be employed as a highly malignant tumor model as its tumorigenicity increases significantly...

Research Grants75

  1. Enzyme therapy for hyperhomocysteinemia
    Yuying Tan; Fiscal Year: 2005
    ..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
  2. Dual-color tumor-host imaging models
    Meng Yang; Fiscal Year: 2007
    ..These models have significant commercial potential for discovery and development of stroma-targeted and anti-angiogenesis drugs. [unreadable] [unreadable] [unreadable]..
  3. Discovery of novel fluorescent reporter genes
    Ming Zhao; Fiscal Year: 2004
    ..Reporters with spectral properties that can be used for whole-body imaging of tumors in the lung and their metastases will be candidates for further development for numerous applications of multi-color imaging. ..
  4. Targeted tumoricidal bacteria
    Ming Zhao; Fiscal Year: 2007
    ..Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]..
  5. Imageable tumor-targeting bacteria
    Ming Zhao; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  6. Therapeutic hair follicle-derived neurospheres
    Meng Yang; Fiscal Year: 2007
    ..Human hair- follicle bulge cells will be further characterized and developed for therapeutic potential for nerve regeneration in Phase III. [unreadable]..
  7. RHOMOCYCSTEINASE FOR HOMOCYSTEINE ASSAY
    Yuying Tan; Fiscal Year: 2002
    ..The tHCY enzymatic kits for these applications will be ready for commercial launch at this point. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  8. Adenoviral GFP targeting of metastatic human tumors using multiple delivery route
    Hiroyuki Kishimoto; Fiscal Year: 2008
    ..Having obtained these results, we can move forward in the Phase II grant application with experiments to bring OBP-401 to the clinic for use in cancer surgery in human patients. [unreadable] [unreadable] [unreadable]..
  9. Orthotopic models of tumor angiogenesis and blood flow
    Meng Yang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  10. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
  11. Significance of Genetic Alterations in Neuroblastoma
    John Maris; Fiscal Year: 2006
    ..It is expected that these will be of prognostic importance and serve as specific targets for developmental therapeutics. ..
  12. ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE
    John Maris; Fiscal Year: 2006
    ..Ultimately, these experiments should lead to the identification of a common pathway to neuroblastoma tumorigenesis that will be an outstanding target for rationally designed therapeutics. ..
  13. INHIBITION OF THE ANGIOGENIC RESPONSE
    Luisa Iruela Arispe; Fiscal Year: 2006
    ..abstract_text> ..
  14. SUPPRESSION OF VASCULAR GROWTH
    Luisa Iruela Arispe; Fiscal Year: 2008
    ..We anticipate that results from these experiments will shed light into the biology of tumor growth and angiogenesis. ..
  15. Metabolomics and metabolic compartmentation in the brain
    Julian Griffin; Fiscal Year: 2006
    ..To correlate NMR observable metabolite changes with transcriptional changes. Our data will provide proof-of principle for this methodology, and establish a means for exploring other neurolodegenerative disorders. ..
  16. Beta glucan enhances antibody therapy for neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2003
    ..These findings will have general implications for antibody and vaccine strategies in human cancer models, and the role of polysaccharides as complementary/herbal medicine in immune-based therapies. ..
  17. Design and Analysis for Cancer Epidemiology Studies
    Ming Tan; Fiscal Year: 2006
    ..abstract_text> ..
  18. Novel Cationic 99mTc Complexes for Heart Imaging
    Shuang Liu; Fiscal Year: 2006
    ..Successful development of new 99mTc perfusion imaging agents will have a profound impact on diagnostic evaluation, risk stratification, and therapeutic decision-making in patients with CAD. ..
  19. Design & Analysis of Preclinical Combination Studies
    Ming Tan; Fiscal Year: 2007
    ..abstract_text> ..
  20. Novel Ternary Ligand 99m Tc-Nitrido Complexes as Heart Imaging Agents
    Shuang Liu; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  21. Regulation of Vascular Function by Progesterone Receptor
    Luisa Iruela Arispe; Fiscal Year: 2007
    ..abstract_text> ..
  22. A novel set of molecular markers to measure metastatic neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2007
    ..Armed with the tools to collect samples expeditiously and to measure MRD accurately, the paradigm of treating subclinical NB can then be tested in multicenter randomized studies. [unreadable] [unreadable]..
  23. Preclin. model for prevention of NSCLC in former smokers
    HILDEGARD SCHULLER; Fiscal Year: 2006
    ....
  24. Tumor-induced immune suppression.
    Suzanne Ostrand Rosenberg; Fiscal Year: 2010
    ..abstract_text> ..
  25. HIGH EFFICIENCY LYMPHOCYTE LABELING FOR IN VIVO TRACKING
    Ralph Weissleder; Fiscal Year: 2004
    ..Furthermore, the investigators believe that the proposed research is in the widest interest to the current NIAID program and other research programs in further developing robust tools to track immune cells in vivo. ..
  26. ENHANCED THERAPY RESPONSE IN OSTEOSARCOMA
    GENE DIRESTA; Fiscal Year: 2001
    ..The MSKCC Therapeutics faculty believes that the ALS, if successful in this model, has promise as an adjunct for limb salvage procedures and in the treatment of many unresectable or disfiguring tumors. ..
  27. Angiogenesis and Microcirculation Gordon Conference
    Luisa Iruela Arispe; Fiscal Year: 2005
    ..The conference will be held in Salve Regina University from August 10-15, 2003. ..
  28. REGULATION OF POLYPLOIDY BY CYTIDYLYLTRANSFERASE (CT)
    Zheng Cui; Fiscal Year: 2002
    ..A better understanding of the mechanism that underlines the genome instability in cancer cells will be helpful for designing more efficient strategies of treating cancer. ..
  29. LCDIO FOR LYMPH NODE MR IMAGING
    Ralph Weissleder; Fiscal Year: 2001
    ..abstract_text> ..
  30. MoAbs for the Management of Pancreatic Cancer
    David Gold; Fiscal Year: 2005
    ..Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody. ..
  31. THERAPEUTIC ANTIANGIOGENESIS
    Luisa Iruela Arispe; Fiscal Year: 2002
    ..abstract_text> ..
  32. Angiogenesis:Novel Basic Science Insight & Human Therapy
    Napoleone Ferrara; Fiscal Year: 2004
    ..abstract_text> ..
  33. MR IMAGING OF GENE EXPRESSION
    Ralph Weissleder; Fiscal Year: 2004
    ..The long-term goal of this research is to extend the capabilities of MR and apply it to in vivo imaging of gene expression. ..
  34. Tumor cell antigen presentation to CD4 + T lymphocytes
    Suzanne Ostrand Rosenberg; Fiscal Year: 2004
    ..of anti-tumor immunity? Which effector cells, cytokines, and chemokines are induced during therapy? 5) Does tumor burden correlate with tumor-induced immuno-suppression? Does surgical removal of primary tumor reverse mmuno-suppression? ..
  35. MR imaging of myeloperoxidase activity
    Ralph Weissleder; Fiscal Year: 2007
    ..The ultimate goal of this research is to develop clinically useful imaging tools for the molecular assessment of atherosclerosis in vivo, which are currently limited. [unreadable] [unreadable] [unreadable]..
  36. Diffuse optical tomography system for molecular imaging
    Ralph Weissleder; Fiscal Year: 2005
    ....
  37. NNK, Beta-Adrenergic AA Release and Lung Cancer
    HILDEGARD SCHULLER; Fiscal Year: 2005
    ..2. To determine which products of the AA cascade are formed in untreated cells and in response to NNK, which of these products stimulate DNA synthesis, and what downstream effectors are activated by these products. ..
  38. MODULATION OF COLON CARCINOGENESIS BY CHLOROPHYLLIN
    Roderick Dashwood; Fiscal Year: 2008
    ..3C. Determine CHL effects on beta-catenin nuclear export and Adherins junction remodeling. 3D. Assess direct effects of CHL on a downstream target of beta-catenin, c-Jun. ..
  39. Quantification of Blood Volume Flow Using Ultrasound
    JEFFREY B FOWLKES; Fiscal Year: 2010
    ....
  40. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2009
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  41. MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY
    Ruiwen Zhang; Fiscal Year: 2002
    ..abstract_text> ..
  42. Mechanism of Chaperone-Mediated Tumor Rejection
    Christopher Nicchitta; Fiscal Year: 2008
    ..abstract_text> ..
  43. Tissue-Specific Optical Imaging Agents and Methods
    Samuel Achilefu; Fiscal Year: 2007
    ..Products of this study will also be made available to other investigators interested in molecular-probe- mediated optical imaging and related medical/pharmaceutical applications. ..
  44. Differentiation of Glioma from Radiation Injury Using Cellular MRI
    Syed Ali; Fiscal Year: 2008
    ..This magnetic labeling technique will also help investigators to track the injected CTL in the body as well as in the targeted areas by magnetic resonance imaging (MRI). [unreadable] [unreadable] [unreadable]..
  45. COLON CANCER--MOLECULAR BIOLOGY OF CELL RESPONSE TO DIET
    Leonard Augenlicht; Fiscal Year: 2001
    ....
  46. How Anthrax lethal factor kills activated macrophages
    Michael Karin; Fiscal Year: 2003
    ..anthracis and its host, this project should enable the design of new therapeutic strategies that will tilt the balance in favor of the host macrophage in the battle against B. anthracis and inhalation anthrax. ..
  47. Assessment of Stem Cell Therapy of Infarcted Myocardium
    Rong Zhou; Fiscal Year: 2004
    ..Finally, developing these imaging techniques on a murine myocardial infarct model allows the utilization of transgenic or knockout mouse models in the future. ..
  48. Resveratrol and Human Melanoma
    Richard Niles; Fiscal Year: 2004
    ..Also the information derived from the metabolism and molecular mechanism studies could provide insights into improving/maximizing the biological activity of resveratrol. ..
  49. MULTIMODAL DOT-PET MOLECULAR PROBES AND TANDEM SYSTEM
    Joseph P Culver; Fiscal Year: 2010
    ..abstract_text> ..
  50. SITE SPECIFICITY OF GASTROINTESTINAL TUMORIGENESIS
    Leonard Augenlicht; Fiscal Year: 2004
    ..Lastly, using microarray analyses, the profiles of gene expression that characterize genetic and dietary modulation of risk will be defined. ..
  51. ATRA effect on myeloid cell differentiation in cancer
    Dmitry Gabrilovich; Fiscal Year: 2005
    ..In the proposed clinical trial we will test the hypothesis that ATRA eliminates immature myeloid cells and improves differentiation of DC in cancer patients. If proven this approach can be used to enhance the effects of cancer vaccines. ..
  52. Imaging Lymphatic Clearance in Tumor Metastasis
    Zaver Bhujwalla; Fiscal Year: 2003
    ..abstract_text> ..
  53. The regulation of tumor immunity by NKT cells
    Mark Smyth; Fiscal Year: 2007
    ..This proposal focuses clearly on a pivotal immune control mechanism that will influence many current and future immunotherapies. ..
  54. Role of WRN in Longevity Assurance
    Judith Campisi; Fiscal Year: 2008
    ..abstract_text> ..
  55. Vascular Heterogeneity Determination by Marrow Progenit*
    Shahin Rafii; Fiscal Year: 2006
    ..These studies will lay the foundation for using BM-marrow derived cells for therapeutic cell therapy to enhance organ (i.e. lung, marrow) revascularization. ..
  56. Image-Guided Delivery and Image-Guided Evaluation of Target and Non-Target Tissue
    Vikas Kundra; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  57. Southwest In Vivo Cellular and Molecular Imaging Center
    Ralph Mason; Fiscal Year: 2003
    ..Thus, we foresee developments from the bench to the bedside, and viewbox, with iterative loops to define the utility of cancer imaging. ..
  58. NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORS
    Albert Wong; Fiscal Year: 2009
    ..abstract_text> ..
  59. CTGF in Pancreatic Tumor Growth
    Amato J Giaccia; Fiscal Year: 2010
    ..In summary, the proposed studies are intended to address an important mechanism by which CTGF affects tumor progression in pancreatic cancers and to determine how effective it is in combination therapy to bring it to the clinic. ..
  60. HYPOXIA AND GENE REPRESSION
    Amato Giaccia; Fiscal Year: 2009
    ..We will test these hypotheses through a combination of genetic and biochemical approaches in cell lines and in mice. ..
  61. Breast Tissue ablation by Conductive Heating
    Gal Shafirstein; Fiscal Year: 2007
    ..It can also be applied, through further research, to other types of cancers (e.g. lung, kidney, head and neck) that involve surgical resection of solid tumors. [unreadable] [unreadable] [unreadable]..
  62. Induction of allograft tolerance in non-human primates
    Anthony Monaco; Fiscal Year: 2006
    ..This non-radiation based protocol employs two widely used agents, thymoglobulin and rapamycin, in combination with BM, as an easily applied, potentially well tolerated protocol for clinical tolerance induction. ..
  63. Induction of Tolerance to Allografts
    Anthony Monaco; Fiscal Year: 2004
    ..abstract_text> ..
  64. Design of Gene Delivery System to Target Hepatocytes
    Mark Davis; Fiscal Year: 2008
    ..The long-term objective of our proposal is to design and engineer a generalized, synthetic system for ultimately delivering nucleic acid-based therapeutics to hepatocytes in humans. ..
  65. Targeted Delivery of Anthrax Inhibitors
    Marina Backer; Fiscal Year: 2007
    ..In Phase II we will develop LFn-liposomes with combination of LF and EF inhibitors, validate these liposomes in animal models of anthrax infection, and pre-clinical steps required for IND filing. [unreadable] [unreadable] [unreadable]..
  66. Changes in Functional Status Across Therapy for Primary Glioma
    Lee Jones; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  67. Imaging Vaccina Viral-Host Pathogenesis
    Gary Luker; Fiscal Year: 2007
    ..Collectively, the research is expected to facilitate the development of improved vaccines and treatments for smallpox, thereby enhancing our ability to prevent the use of smallpox for bioterrorism. [unreadable] [unreadable] [unreadable]..
  68. Chemoprevention of Esophageal Squamous Cell Carcinoma
    Gary Stoner; Fiscal Year: 2004
    ..abstract_text> ..
  69. The Role of Chfr In Tumorigenesis
    Zheng Fu; Fiscal Year: 2007
    ..abstract_text> ..
  70. Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer
    Marina Backer; Fiscal Year: 2008
    ..We expect that this data establish feasibility of clinical development for EGF-SLiP. [unreadable] [unreadable] [unreadable]..